Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 2 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 3 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
14 Sep 2019
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.

Vitamin D therapy improves sexual function in women

30 Apr 2019
Women may actually avoid cancer with higher levels of Vitamin D.

A recent study has shown the efficacy of vitamin D therapy in improving sexual function in women with sexual dysfunction and vitamin D deficiency. Moreover, an improvement in depression symptoms does not appear to facilitate this effect.

Women aged 18–45 years with sexual dysfunction, defined as a Female Sexual Functioning Index (FSFI) score <26.55, and serum 25[OH]D <30 ng/ml were recruited in this randomized, double-blind, placebo-controlled trial that examined the effect of vitamin D therapy on sexual function.

Participants received either an intramuscular injection of 300,000 IU cholecalciferol or a placebo at baseline and then after 4 weeks. FSFI was used to assess sexual function at baseline and at 4 and 8 weeks. The authors measured the serum level of 25[OH]D and evaluated depression symptoms using the Beck Depression Inventory (BDI) at baseline and 8 weeks.

There were 38 women in each group who completed the study. Only those in the cholecalciferol group showed an increase in serum 25[OH]D levels by a mean of 14.4±3.2 ng/ml (p<0.001).

The intervention group also registered a higher FSFI score compared with the placebo group at week 4 (19.6 vs 16.3; p=0.002) and week 8 (25.0 vs 17.1; p<0.001). A significant reduction in BDI score was achieved by participants in the cholecalciferol group (mean, –21.0±12.3; p<0.001).

“The effect of treatment on sexual function was independent of its effect on depression symptoms,” the authors said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 2 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 3 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
14 Sep 2019
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.